Keywords
blood loss, ovarian primary cancers, colorectal primary, CRS, adenocarcinoma
BLOOD LOSS, INVASIVE CANCER, ADENOCARCINOMA, POSTOPERATIVE COMPLICATIONS
Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is the standard-of-care treatment modality for selected patients with peritoneal surface malignancy (PSM). It has been studied extensively in appendiceal and ovarian primary cancers, as well as colorectal, primary peritoneal, and gastric cancer. A drawback of this therapy is the invasive nature of the procedures and associated morbidity. Open CRS/HIPEC is typically performed through a xiphoid-to-pubis incision and carries a significant risk of postoperative morbidity, on the order of 33 to 63% [Several studies have demonstrated decreased postoperative morbidity and improvements in short-term postoperative outcomes, such as blood loss, and length of stay, with a laparoscopic approach [Patients with low-grade PSM are those who are likely to have the best long-term outcomes following CRS/HIPEC. Additionally, these patients are least likely to have their oncologic outcomes affected by postoperative complications, as these are not invasive cancers [We conducted a prospective clinical trial of laparoscopic CRS/HIPEC for patients with PSM of appendiceal or colorectal primary origin, inclusive of adenocarcinoma histology, with PCI 